Mapi Pharma is Seeking New Depot Product Partnerships

Core Insights - Mapi Pharma Ltd. is participating in the 7th Annual Evercore HealthCONx Conference from December 3-5, 2024, in Coral Gables, Florida, to explore partnership opportunities for its innovative long-acting depot injectable treatments [1][2]. Company Overview - Mapi Pharma is a fully integrated, late-stage clinical development biopharmaceutical company focused on developing Lifecycle Management products using extended-release Depot technologies across various therapeutic areas, including multiple sclerosis (MS), diabetes, and schizophrenia [3][6]. - The company has a strong intellectual property (IP) portfolio and is engaged in the development of high barrier-to-entry and high added-value life cycle management products [6]. Development and Manufacturing Capabilities - Mapi Pharma has a large-scale, state-of-the-art GMP approved manufacturing facility for both clinical development and commercial supply, allowing for efficient integration of R&D, clinical studies, registration, and manufacturing [4]. - The company has a dedicated R&D team and Depot labs, which enhance its capabilities in developing Depot products [4]. Partnership Opportunities - Mapi Pharma is actively seeking partnerships for its proprietary Depot products, including Deutetrabenazine (AUSTEDO® XR) Depot for Huntington's disease and Anastrazole (Arimidex®) Depot for hormone receptor-positive early breast cancer [5]. - The company offers to conduct formulation development, preclinical studies, and manage clinical development for partners, who will finance development costs and handle commercialization [5]. Product Pipeline - Mapi's lead product, GA Depot, is partnered with Viatris for the treatment of Relapsing Forms of Multiple Sclerosis (RMS) and is currently under FDA review following successful Phase 3 results [6]. - The company is also developing Depot drugs for various conditions, including schizophrenia, diabetes, weight control, Parkinson's disease, and potentially Alzheimer's [6].